Company Overview - Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines to address serious unmet medical needs, particularly in oncology [6] - The company aims to integrate traditional biology research with advanced engineering to expedite the development of better medicines [6] Initial Public Offering (IPO) Details - Eikon has priced its upsized initial public offering at $18.00 per share, offering a total of 21,177,600 shares, which is expected to generate approximately $381 million in gross proceeds [1] - The underwriters have a 30-day option to purchase an additional 3,176,640 shares at the same initial public offering price [1] - The IPO is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "EIKN" on February 5, 2026, with the offering expected to close on or about February 6, 2026 [2] Regulatory and Compliance Information - A registration statement on Form S-1 related to the offering has been filed with the SEC and was declared effective on January 30, 2026 [3] - The offering is being conducted solely through a prospectus that is part of the effective registration statement [4]
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering